Role of Psychedelics in Treatment-Resistant Depression.
The Psychiatric clinics of North America June 1, 2023 Shubham Kamal, Manish Kumar Jha, Rajiv Radhakrishnan 32 citations
Interest in using psychedelics to treat treatment-resistant depression is growing, but evidence for classic psychedelics like psilocybin, LSD, and ayahuasca/DMT remains limited, though early results are promising. Atypical psychedelics such as ketamine have also been studied. Researchers caution that the field may be experiencing a hype bubble. Future work should identify the essential components of psychedelic therapies and their neurobiological mechanisms to support clinical adoption.